Paradoxically, in breast cancer, PRMT7 methylates eukaryotic translation initiation factor 2α (eIF2α) to promote drug resistance [30], whereas in renal-cell carcinoma, it methylates β-catenin to enhance its stability and promote proliferation [33]. Here, EIF2A is linked to breast carcinoma.